ICH Q12: Established Conditions and Why They Matter

ICH Q12 is the guideline on pharmaceutical product lifecycle management. It exists to answer a question the earlier guidelines left open: which parts of a dossier are actually binding, such that changing them requires telling a regulator.

Before Q12, that was inferred. A sponsor reading its own approved Module 3 could not always tell which sentence was a commitment and which was description. The practical consequence was over-reporting: if you cannot tell what is binding, you report everything.

Established conditions

An established condition (EC) is an element in the dossier that is considered necessary to assure product quality, and which therefore requires a regulatory submission if changed.

Anything not an established condition can be changed under your own change control system without a filing.

Q12 describes two ways to identify them:

• A parameter-based approach, listing inputs and process parameters.
• An enhanced approach, where a stronger understanding of the process lets you define ECs at a higher level, typically around performance rather than around every parameter.

The enhanced approach is the point. Demonstrated process understanding buys you regulatory flexibility, because a well-justified control strategy makes fewer individual parameters load-bearing.

Post-Approval Change Management Protocol

A PACMP is agreement in advance. You describe a change you intend to make later, the tests and studies that would demonstrate it is acceptable, and the acceptance criteria. A regulator reviews and approves that protocol.

When you make the change, you execute the protocol and report at a lower category than the change would otherwise have carried.

This is the most concrete benefit in Q12 for a company that knows it will move a site, scale a process, or change a supplier in the next few years. The regulatory work is front-loaded into a period when nothing is urgent.

Product Lifecycle Management document

The PLCM document is a summary that pulls the lifecycle picture into one place: the established conditions, the reporting category for changes to them, any PACMPs, and post-approval commitments. It is intended as a single reference for both sponsor and reviewer.

What FDA has actually adopted

This matters more than the guideline's contents.

FDA has published Q12 as guidance, but with a stated position that the established conditions concept is not consistent with current US law and regulation. FDA's existing framework in 21 CFR 314.70 and 601.12 governs reporting categories in the United States.

The practical reading: PACMPs and the lifecycle management thinking in Q12 are usable with FDA, and the EC framework as a way of overriding US reporting categories is not. In the EU and other ICH regions, ECs carry more weight.

Do not build a US regulatory strategy on established conditions displacing 314.70.